New Ideas in Allergen-Specific Immunotherapy

Mailing, H.‐J.

doi:10.2500/105065890782018136

Cited by 8 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, the only parameters indicating efficacy of a treatment are reduction in symptoms and/or drug intake (2). Furthermore, the degree of reduction in symptoms and/or drug intake should be of a magnitude that, from a clinical point of view, significantly reduces the morbidity of allergic disorders (3). This can be estimated either by investigating the reduction in symptom/medication scores in relation to a pretreatment observation period (a season for seasonal allergies or a sufficiently long comparative period in the case of perennial allergies), or by comparing matched groups treated by active immunotherapy and by placebo.…”

Section: Estimation Of Clinical Efficacymentioning

confidence: 99%

Immunotherapy as an effective tool in allergy treatment

Mailing¹

1998

Allergy

154

100

View full text Add to dashboard Cite

Section: Estimation Of Clinical Efficacymentioning

confidence: 99%

Immunotherapy as an effective tool in allergy treatment

Mailing¹

1998

Allergy

154

100

View full text Add to dashboard Cite

“…e.g. -25% reduction in symptom b score/drug intake may be statistically significant but not relevant to the patient [13]. With this in mind the design of the study was scheduled by taking these factors into consideration 1) Group of polysensitized patients.…”

Section: Discussionmentioning

confidence: 99%

Clinical Efficacy of Allergen Specific Immunotherapy (ASIT) in Allergic Rhinitis

Sukhesh¹

2011

IJCM

View full text Add to dashboard Cite

Though efficacy of Allergen Specific Immunotherapy (ASIT) has been proved in many studies, reports about success in clinical practice and under field conditions in alleviating the suffering or decreasing the morbidity in patients of Allergic Rhinitis are few. 260 patients of Allergic Rhinitis without coexisting diseases were included. Skin prick test was done on all patients. ASIT was initiated with common inhalant indoor allergens as per standard protocol and patients were assessed at the start and at 2 m, 6 m and 18 months of ASIT. ASIT was able to significantly reduce the symptom score in all the three groups namely sneezing, rhinorrhoea and nasal itching (p < 0.001). Concurrently it was also able to produce a significant reduction in the usage of concomitant drug intake (p < 0.001) thereby implying a decrease in morbidity. When assessed regarding clinical efficacy, ASIT was found to be satisfactory or highly effective in more than 75% patients. ASIT has got a role in clinical practice in polysensitized patients in field conditions. This is based on the evidence that besides decrease in hypersensitivity/symptoms, it also has an effect on minimizing the necessity of taking drugs to relieve the symptoms, which has strong implications of economics and toxicity, while treating patients

show abstract

“…The clinical efficacy of immunotherapy treatment protocols has been documented in a number of studies involving rhinitis and asthma patients, although asthma, because of the multifactorial pathophysiology involved, may not respond as satisfactorily as rhinitis to immunotherapy. 4 Immunotherapy is inappropriate for food allergy and is not indicated for eczema, urticaria, or angioedema.…”

mentioning

confidence: 99%

Modified Allergen Immunotherapy: Effect on Immunoglobulin E Production

Babakhin¹,

Хаитов²,

Петров³

1995

allergy asthma proc

View full text Add to dashboard Cite

New forms of allergen immunotherapy are proposed employing modified allergens that induce T-cell responses without associated increased IgE-related responses. Synthetic polyelectrolytes attached to an analyte may modulate T-and 8-cellfunction, producing effective desensitization and altering immunoglobulin production dependent on the physico-chemical nature of the carrier molecule. (Allergy Proc 16, 4:195-202, 1995) S pecific hyposensitivity or specific immunotherapy for treatment of Type I hypersensitivity was first applied as oral allergen immunotherapy by Curtis] and as subcutaneous immunotherapy by Noon and Freeman.2,3 Since then, immunotherapy has been used extensively and represents the only allergen-specific treatment of allergic diseases. The clinical efficacy of immunotherapy treatment protocols has been documented in a number of studies involving rhinitis and asthma patients, although asthma, because of the multifactorial pathophysiology involved, may not respond as satisfactorily as rhinitis to immunotherapy.4 Immunotherapy is inappropriate for food allergy and is not indicated for eczema, urticaria, or angioedema.The primary clinical goal of specific immunotherapy is to reduce the patient's immune response-related symptoms to a given allergen. Although the mechanisms of immunotherapy are still poorly understood, successful specific immunotherapy generally results in the follow- Russian Federal Institute of Immunology and Academy of Sciences of Russia, Moscow Address correspondence and reprint requests to AlexanderAllergy Proc.ing: 1) reduction of both polyclonal and allergen-specific 19B; 2) increase of allergen specific "blocking" 19B antibodies; 3) reduction of mediator release from basophil and mast cells; 4) suppression of late phase reactions by inhibiting recruitment of inflammatory cells; 5) decrease of proliferative response and Iymphokine production upon allergen challenge; 6) generation of allergenspecific suppressor cells; and 7) inhibition of IL-4 production and/or enhancement of IFN-'Y production by allergen specific T-cells. Immunotherapy initially produces an increase in specific 19B in the serum, although longer treatment often results in a decline of specific 19B levels.The inhibition of allergic reactivity is the primary goal of immunotherapy, and the changing of antibody production to allergen from 19B to other isotypes may play an important role in successful immunotherapy. Clinical efficacy of immunotherapy may be improved and the risk of side effects reduced by the use of modified allergens.Thus, the suppression of 19B response could be achieved by inoculation of allergen-autologous antibody complexes,5-7 or the combination of passive and active immunization. 8 Alternatively, simultaneous administration of allergens with immunosuppressive agents such as cyclosporin A may enhance induction of specific nomesponsiveness,9In previous years, various attempts have been made to improve specific immunotherapy, These approaches included: 1) varying the modes of administration; 2) stan...

show abstract

New Ideas in Allergen-Specific Immunotherapy

Cited by 8 publications

References 13 publications

Immunotherapy as an effective tool in allergy treatment

Immunotherapy as an effective tool in allergy treatment

Clinical Efficacy of Allergen Specific Immunotherapy (ASIT) in Allergic Rhinitis

Modified Allergen Immunotherapy: Effect on Immunoglobulin E Production

Contact Info

Product

Resources

About